Publications by authors named "Raphael Bejuit"

Claim this Profile
I
Identification of risk profiles for liver injury in adults with multiple sclerosis using artificial intelligence method.
Dominique Larrey, Fang Liz Zhou, Claire Brulle-Wohlhueter, Myriam Benamor, Jeffrey Chavin, Raphael Bejuit

Mult Scler Relat Disord· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of CD40L with Frexalimab in Multiple Sclerosis.
Patrick Vermersch, Cristina Granziera, Yang Mao-Draayer, Gary Cutter, Oleksandr Kalbus, Raphael Bejuit

N Engl J Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, open-label, phase 2a study to evaluate the contribution of artefenomel to the clinical and parasiticidal activity of artefenomel plus ferroquine in African patients with uncomplicated Plasmodium falciparum malaria.
Adama Gansane, Moussa Lingani, Adoke Yeka, Alain Nahum, Marielle Bouyou-Akotet, Raphaël Bejuit

Malar J· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project).
Roberto Bernabei, Francesco Landi, Riccardo Calvani, Matteo Cesari, Susanna Del Signore, Raphael Bejuit

BMJ· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malaria.
Yeka Adoke, Rella Zoleko-Manego, Serge Ouoba, Alfred B Tiono, Grace Kaguthi, Raphaël Bejuit

Malar J· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis.
Yannick Allanore, Peter Wung, Christina Soubrane, Corinne Esperet, Frederic Marrache, Raphael Bejuit

Ann Rheum Dis· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772).
Ganesh Raghu, Luca Richeldi, Bruno Crestani, Peter Wung, Raphael Bejuit

Eur Respir J· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The "Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies" (SPRINTT) randomized controlled trial: Case finding, screening and characteristics of eligible participants.
Emanuele Marzetti, Matteo Cesari, Riccardo Calvani, Jérôme Msihid, Matteo Tosato, Raphaël Bejuit

Exp Gerontol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The "Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies" (SPRINTT) randomized controlled trial: design and methods.
Francesco Landi, Matteo Cesari, Riccardo Calvani, Antonio Cherubini, Mauro Di Bari, Raphael Bejuit

Aging Clin Exp Res· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis